SLGL实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	15 208.00
平均成交量	30 420.00
市值	23.69M
EPS	$0 ( 2024-03-15 )
下一个收益日期	( $-0.150 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.840
ATR14	$0.0420 (4.94%)

Sol Gel Technologies Ltd 相关性

10 最正相关
SIRI	0.864
CARE	0.862
FXNC	0.856
CFB	0.849
SFST	0.839
NFBK	0.839
HAIN	0.838
ACLS	0.836
OTEX	0.831
TTEC	0.829

10 最负相关
FRLA	-0.832
INCR	-0.832
VITL	-0.826
VTVT	-0.826
IXAQ	-0.819
TRMR	-0.818
TWLVU	-0.813
KNTK	-0.811
RIVE	-0.809
PWP	-0.807

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Sol Gel Technologies Ltd 财务报表

Annual	2023
营收:	$1.55M
毛利润:	$1.21M (77.99 %)
EPS:	$-1.010

FY	2023
营收:	$1.55M
毛利润:	$1.21M (77.99 %)
EPS:	$-1.010

FY	2022
营收:	$3.88M
毛利润:	$-8.80M (-226.60 %)
EPS:	$-0.590

FY	2021
营收:	$31.27M
毛利润:	$0.00 (0.00 %)
EPS:	$0.140

Financial Reports:

No articles found.

Sol Gel Technologies Ltd

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.